Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABSTRACT: Background The BCR-ABL-negative myeloproliferative neoplasms, i.e., polycythemia vera, essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by mutations in JAK2, CALR, or MPL.
|
30889303 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/10<sup>4</sup>ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91).
|
30612065 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After 5 months, BCR-ABL fusion signals decreased to 5%, and myelofibrosis improved from MF Grade 2 to 1; she then underwent allogeneic bone marrow transplantation from an unrelated donor.
|
30879266 |
2019 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF.
|
29560522 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a clinical manifestation of chronic BCR-ABL1-negative chronic myeloproliferative neoplasms.
|
29562644 |
2018 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN).
|
29256926 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia.
|
27539616 |
2017 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively.
|
28335073 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clonal hematologic diseases of the blood such as polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL negative Myeloproliferative Neoplasms (MPN).
|
28914569 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative MPN is a subcategory that includes primary myelofibrosis (MF), post-essential thrombocythemia MF, and post-polycythemia vera MF.
|
28499938 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET).
|
29134817 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis is a BCR-ABL-negative myeloproliferative neoplasm characterized by abnormal hematopoiesis.
|
27672139 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia.
|
28543980 |
2017 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 1960, Nowell and Hungerford discovered an invariable association between the Philadelphia chromosome (subsequently shown to harbor the causal BCR-ABL1 mutation) and CML; accordingly, the term MPN is primarily reserved for PV, ET, and PMF, although it includes other related clinicopathologic entities, according to the World Health Organization (WHO) classification system.
|
26492355 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classic BCR-ABL1-negative myeloproliferative neoplasm is an operational sub-category of MPNs that includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
27039813 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling.
|
27017614 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival.
|
27756071 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
|
26933174 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.
|
26181658 |
2015 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF.
|
26182311 |
2015 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely polycythemia vera, essential thombocythemia and primary myelofibrosis has relied significantly on the detection of known causative mutations in the JAK2 or MPL genes, which account for the majority of MPN patients.
|
25349114 |
2015 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polycythaemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (MF), are the most common myeloproliferative neoplasms (MPN) in patients without the BCR-ABL1 gene rearrangement.
|
23986553 |
2014 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines.
|
25232060 |
2014 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
|
25520049 |
2014 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells.
|
24190690 |
2013 |